Rising Cancer Prevalence Drives Growth In The Oncolytic Virus Therapy Market: A Key Driver Powering Oncolytic Virus Therapy Market Growth In 2025

The Oncolytic Virus Therapy Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current Oncolytic Virus Therapy Market Size and Its Estimated Growth Rate?
The size of the oncolytic virus therapy market has experienced substantial growth in the past few years. It is projected to expand from $0.19 billion in 2024 to $0.23 billion in 2025, with a compound annual growth rate (CAGR) of 25.4%. The notable growth in the preceding period can be credited to advancements in genetic engineering methods, heightened comprehension of the tumor microenvironment, clinical breakthroughs and regulatory authorizations, the increasing prominence of immunotherapy in combating cancer, and progress made in gene delivery systems.

The market for oncolytic virus therapy is predicted to undergo significant expansion over the next couple of years. In 2029, the market size is projected to reach $0.55 billion, showing a compound annual growth rate (CAGR) of 23.7%. This anticipated growth through the forecast duration will likely be driven by factors such as the broadening of oncolytic virus platforms, combined treatment strategies with immune checkpoint inhibitors, tailored medical approaches, an escalated scale of clinical trials, and policy-based support and guiding principles. The forecast period will also see certain trending developments like technological progression in delivery systems, breakthroughs in synthetic biology, biopharmaceutical industry-based collaborations and alliances, advances in the field of virology and immunology, and a heightened emphasis on paediatric oncology.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12391

How Are Emerging Segments Shaping the Oncolytic Virus Therapy Market Landscape?
The oncolytic virus therapy market covered in this report is segmented -

1) By Therapy Type: HSV-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, NDV (Newcastle Disease Virus), Other Therapy Types
2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses
3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer
4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Subsegments:
1) By HSV-Based Oncolytic Virus Therapy: Talimogene Laherparepvec (T-VEC), Other HSV-Based Therapies
2) By Adenovirus-Based Oncolytic Virus Therapy: Onyx-015, AdV-5/3-D24, Other Adenovirus-Based Therapies
3) By Reovirus: Reolysin, Other Reovirus Therapies
4) By Poxviruses: JX-594 (OncoVac), Other Poxvirus Therapies
5) By NDV (Newcastle Disease Virus): NDV-Based Therapies, Other NDV Applications
6) By Other Therapy Types: Combination Therapies, Other Emerging Oncolytic Virus Therapies

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

Which Growth Factors Are Influencing Oncolytic Virus Therapy Market Expansion?
The anticipated rise in cancer cases is predicted to boost the expansion of the oncolytic virus therapy market. Cancer refers to a set of diseases that are identified by the unregulated growth and proliferation of irregular cells within the body. Oncolytic virus therapy presents an opportunity to discriminate and eradicate cancer cells, while also stimulating an immune response against the tumor, offering a dual-pronged approach for effective cancer management. For example, the American Cancer Society Inc., a non-profit organization based in the US, projected in January 2023 that there would be 609,820 deaths due to cancer and 1,958,310 new cancer diagnoses in the US in 2022. Consequently, the escalating incidence of cancer is fueling the oncolytic virus therapy market's growth.

Who Are the Dominant Players Across Different Oncolytic Virus Therapy Market Segments?
Major companies operating in the oncolytic virus therapy market include Pfizer Inc., Johnson & Johnson, Sorrento Therapeutics Inc., AbbVie Inc., AstraZeneca plc, Amgen Inc., Boehringer Ingelheim Group, Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Kissei Pharmaceutical Co. Ltd., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Adze Biotechnology, Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Circio Holding ASA, Lokon Pharma AB, Provectus Biopharmaceuticals Inc., Vibalogics

What Are the Latest Developing Trends in the Oncolytic Virus Therapy Market?
Main players in the oncolytic virus therapy market are focusing on gaining regulatory clearances to speed up the launch of novel cancer treatments. These regulatory clearances involve health bodies reviewing and approving the use of medical products like drugs, biologics, and medical devices in the market. For example, in March 2024, the FDA granted ImmVira, a biotechnology firm based in China, Fast Track status for its oncolytic virus therapy MVR-T3011 IT, which is aimed at treating patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have shown disease progression following platinum-based chemotherapy and a minimum of one previously administered anti-PD-1/PD-L1 therapy. This honour is designed to hasten the development and review process for treatments that tackle serious illnesses with unaddressed medical needs.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

Which Geographic Regions Are Expected to Dominate the Oncolytic Virus Therapy Market in the Coming Years?
North America was the largest region in the oncolytic virus therapy market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Oncolytic Virus Therapy Market?
2. What is the CAGR expected in the Oncolytic Virus Therapy Market?
3. What Are the Key Innovations Transforming the Oncolytic Virus Therapy Industry?
4. Which Region Is Leading the Oncolytic Virus Therapy Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.